Crystallise’s Horizon Scanning service empowers clients with evidence-based foresight on mortality and morbidity risks. We identify impactful technologies using varied data sources—technology patents, biomedical research, clinical trials, and more. Monitoring developments in technologies such as Genetic therapies, CAR-T, Monoclonal antibodies, Immunotherapies, and more conventional drugs/treatments, enables insurers to stay ahead of the curve.
Risk indicators and bespoke reports provide actionable insights into biomedical progress. Moreover, we monitor future developments that might have adverse effects on mortality, such as antibiotic resistance or long-term impacts of COVID-19.